Study of Methodologies to Measure Blood Flow and Oxygenation in Adults With Sickle Cell Disease
A Study of Methodologies to Measure Blood Flow and Oxygenation as Potential Biomarkers in Adults With Sickle Cell Disease
Studieöversikt
Status
Status
Betingelser
Betingelser
Studietyp
Studietyp
Inskrivning (Faktisk)
Inskrivning
Kontakter och platser
Studieorter
-
-
Michigan
-
Detroit, Michigan, Förenta staterna, 48201
- Research Site
-
-
Deltagandekriterier
Urvalskriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
Key Inclusion Criteria:
- Have a diagnosis of SCD confirmed by hemoglobin analysis.
Be in stable clinical condition, as determined by the Investigator.
Subjects enrolled in Part B must also meet the following eligibility criterion at Screening:
- Receiving scheduled standard of care RBC exchange transfusion therapy, with ≥3 transfusions already received.
- Be deemed healthy, as determined by the Investigator, based on the physical examination, medical history, vital signs, 12-lead electrocardiogram (ECG), and clinical laboratory measurements.
Key Exclusion Criteria:
- Inability to lie still for ≥5 minutes, claustrophobia sufficient to interfere with generating reliable MRI scans, body weight exceeding 320.0 lbs., or girth exceeding the magnet bore.
- Presence of a metal device affected by MRI (e.g., any type of electronic, mechanical or magnetic implant, cardiac pacemaker, aneurysm clips, implanted cardiac defibrillator) or potential ferromagnetic foreign body (metal slivers, metal shavings, other metal objects) which would be a contraindication for MRI.
- Acute pain crisis requiring hospitalization, with a discharge ≤4 weeks prior to the first imaging visit, or when determined by the Investigator to not be at steady state.
- Recent (≤3 months) treatment with hydroxyurea therapy.
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: Kohort
- Tidsperspektiv: Blivande
Antal grupper/kohorter
Kohorter och interventioner
Grupp / KohortGrupp / Kohort |
|---|
|
Part A
Cohort 1- Participants with severe SCD (4-10 VOC/year) Cohort 2- Participants with milder SCD (<4-10 VOC/year) Cohort 3- Healthy volunteers Part A and B can occur in parallel
|
|
Part B
Adults with SCD receiving chronic red blood cell exchange transfusion Part A and B can occur in parallel
|
Vad mäter studien?
Primära resultatmått
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Blood flow in the brain of adults with severe SCD (4-10 vaso-occlusive crises [VOC]/ year) compared to healthy adults without SCD as assessed by MRI-ASL (arterial spin labeling)
Tidsram: Up to day 18 post screening visit
|
Up to day 18 post screening visit
|
Sekundära resultatmått
Sekundära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Kidney blood flow rates as assessed by MRI-SWI (susceptibility-weighted imaging)
Tidsram: Up to day 21 post screening visit
|
Up to day 21 post screening visit
|
|
Skeletal muscle blood flow rates as assessed by NIRS
Tidsram: Up to day 21 post screening visit
|
Up to day 21 post screening visit
|
|
Skin blood flow rates as assessed by LSCI
Tidsram: Up to day 21 post screening visit
|
Up to day 21 post screening visit
|
|
Retinal blood flow rates as assessed by OI
Tidsram: Up to day 21 post screening visit
|
Up to day 21 post screening visit
|
|
Total oxygen levels in the brain as assessed by MRI-ASL
Tidsram: Up to day 21 post screening visit
|
Up to day 21 post screening visit
|
|
Total oxygen levels in the kidney as assessed by MRI-SWI
Tidsram: Up to day 21 post screening visit
|
Up to day 21 post screening visit
|
|
Total oxygen levels in the muscle as assessed by NIRS
Tidsram: Up to day 21 post screening visit
|
Up to day 21 post screening visit
|
|
Total oxygen levels in the skin as assessed by LSCI
Tidsram: Up to day 21 post screening visit
|
Up to day 21 post screening visit
|
|
Total oxygen levels in the retina as assessed by OI
Tidsram: Up to day 21 post screening visit
|
Up to day 21 post screening visit
|
Samarbetspartners och utredare
Sponsor
Sponsor
Utredare
Utredare
- Studierektor: Medical Director, Bioverativ Therapeutics Inc.
Studieavstämningsdatum
Studera stora datum
Studiestart
Studiestart
Primärt slutförande (Faktisk)
Primärt slutförande
Avslutad studie (Faktisk)
Avslutad studie
Studieregistreringsdatum
Först inskickad
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Första postat
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste uppdatering publicerad
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
Andra studie-ID-nummer
- 996SC001
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .